Showing results (1-10 of 20) with videos related to
Sort By:
Pageof 2
British Journal of Clinical Pharmacology|February 6, 2026
How the HTAR will contribute to a value-based decision-making for medicinal products across the EURoisin Adams, Michal StanakStatistics in Medicine|February 27, 2013
Incorporating data from various trial designs into a mixed treatment comparison modelSusanne Schmitz, Roisin Adams, Cathal WalshBMC Medical Research Methodology|November 8, 2012
The use of continuous data versus binary data in MTC models: a case study in rheumatoid arthritisSusanne Schmitz, Roisin Adams, Cathal WalshPharmacoeconomics|April 2, 2016
Identifying and Revealing the Importance of Decision-Making Criteria for Health Technology Assessment: A Retrospective Analysis of Reimbursement Recommendations in IrelandSusanne Schmitz, Laura McCullagh, Roisin Adams, et al.Annals of the Rheumatic Diseases|October 1, 2011
A mixed treatment comparison of the efficacy of anti-TNF agents in rheumatoid arthritis for methotrexate non-responders demonstrates differences between treatments: a Bayesian approachSusanne Schmitz, Roisin Adams, Cathal D Walsh, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 28, 2015
Using the Analytic Hierarchy Process to Derive Health State Utilities from Ordinal Preference DataBrian P Reddy, Roisin Adams, Cathal Walsh, et al.Multiple Sclerosis (Houndmills, Basingstoke, England)|February 13, 2013
Relating health-related Quality of Life to disability progression in multiple sclerosis, using the 5-level EQ-5DEmer Fogarty, Cathal Walsh, Roisin Adams, et al.International Journal of Technology Assessment in Health Care|December 12, 2024
Advancing cooperation in Health Technology Assessment in Europe: insights from the EUnetHTA 21 project amidst the evolving legal landscape of European HTAIrene Urbina, Roisin Adams, Judith Fernandez, et al.Pharmacoeconomics|May 15, 2010
Understanding the relationship between the EQ-5D, SF-6D, HAQ and disease activity in inflammatory arthritisRoisin Adams, Cathal Walsh, Douglas Veale, et al.Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|October 1, 2021
Estimating the Theoretical Cost Implications of Funding New Drugs Considered Not to Be Cost-EffectiveCormac Kennedy, Laura McCullagh, Roisin Adams, et al.Pageof 2